EUVIMEDEUVIMED entdecken
Crossref

Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis

Mochong Liao, Shuo Kang

Expert Review of Pharmacoeconomics & Outcomes Research · 2024

DOI: 10.1080/14737167.2023.2267177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Mochong Liao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, PR China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Squamous Cell, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The current study aimed to evaluate the cost-effectiveness of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in China. METHODS: A partitioned survival model was established to track 3-week patients' transition and project the health and economic outputs in 15-year horizon of the two competing options among sintilimab and docetaxel. Clinical data were obtained from the ORIENT-3 trial, and cost and utility values were gathered from the local charges and published studies. Total costs, life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were evaluated. Sensitivity analyses were conducted to assess the robustness of the model outcomes. RESULTS: Base-case results revealed that sintilimab yield marginal cost of $4,700.53 and additional 0.32 QALYs, resulting in an ICER of $14,615.31 per QALY gained, which is lower than the willingness-to-pay threshold of $38,224/QALY in China. One-way sensitivity analyses showed that the cost of best supportive care was the main driver of the ICER, and probabilistic sensitivity analyses demonstrated that the model outputs were robust. CONCLUSIONS: Sintilimab could be considered the cost-effective second-line strategy for patients with advanced or metastatic squamous NSCLC compared with docetaxel in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCarcinoma, Squamous CellAntibodies, Monoclonal, HumanizedHumansDocetaxelCost-Benefit AnalysisCost-Effectiveness Analysis

Stichwörter der Autor:innen

Sintilimabadvanced or metastatic squamous non-small-cell lung cancercost-effectivenessdocetaxelsecond-line treatment

Substanzen

DocetaxelsintilimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Ophthalmology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, PR China.
  • Medical Insurance Office, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, PR China.

Zitieren

APA

Liao, M., & Kang, S. (2024). Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2023.2267177

Vancouver

Liao M, Kang S. Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2023.2267177

BibTeX
@article{Liao2024,
  author = {Liao, Mochong and Kang, Shuo},
  title = {Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2024},
  doi = {10.1080/14737167.2023.2267177}
}
Kostenlos starten →